Avidity Biosciences, Inc. financial data

Symbol
RNA on Nasdaq
Industry
Pharmaceutical Preparations
Location
10578 Science Center Drive, Suite 125, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Avidity Biosciences LLC (to 1/6/2017), Avidity NanoMedicines LLC (to 2/18/2014)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.56K % +47.1%
Debt-to-equity 10.5 % -22.6%
Return On Equity -25.9 % +34.9%
Return On Assets -23.4 % +33%
Operating Margin -3.48K % -41.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares
Common Stock, Shares, Outstanding 120M shares +51.2%
Entity Public Float 4.4B USD +442%
Common Stock, Value, Issued 12K USD +50%
Weighted Average Number of Shares Outstanding, Basic 112M shares +52.8%
Weighted Average Number of Shares Outstanding, Diluted 112M shares +52.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 10.9M USD +14%
Research and Development Expense 304M USD +59%
General and Administrative Expense 86.2M USD +59.1%
Operating Income (Loss) -379M USD -60.8%
Nonoperating Income (Expense) 56.6M USD +142%
Net Income (Loss) Attributable to Parent -322M USD -51.9%
Earnings Per Share, Basic -2.89 USD/shares +0.69%
Earnings Per Share, Diluted -2.89 USD/shares +0.69%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 220M USD +18.8%
Cash, Cash Equivalents, and Short-term Investments 1.5B USD +152%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 5.86M USD
Assets, Current 1.54B USD +152%
Property, Plant and Equipment, Net 12.7M USD +51.2%
Operating Lease, Right-of-Use Asset 5.62M USD -32.1%
Other Assets, Noncurrent 521K USD +73.1%
Assets 1.56B USD +149%
Accounts Payable, Current 8.46M USD -3.95%
Contract with Customer, Liability, Current 21M USD -26%
Liabilities, Current 98M USD +21.5%
Contract with Customer, Liability, Noncurrent 38M USD -7.18%
Operating Lease, Liability, Noncurrent 2.96M USD -52.4%
Liabilities 139M USD +8.72%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.9M USD +2222%
Retained Earnings (Accumulated Deficit) -893M USD -56.5%
Stockholders' Equity Attributable to Parent 1.42B USD +185%
Liabilities and Equity 1.56B USD +149%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -70.4M USD -43.7%
Net Cash Provided by (Used in) Financing Activities 389M USD +1596%
Net Cash Provided by (Used in) Investing Activities -32.7M USD +83.3%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 120M shares +51.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 286M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 223M USD +20.1%
Deferred Tax Assets, Valuation Allowance 272M USD +57.2%
Deferred Tax Assets, Gross 273M USD +56.1%
Operating Lease, Liability 6.8M USD -31%
Depreciation 2.78M USD +32.1%
Payments to Acquire Property, Plant, and Equipment 915K USD -49.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -320M USD -52.6%
Lessee, Operating Lease, Liability, to be Paid 7.49M USD -33%
Property, Plant and Equipment, Gross 20.7M USD +51.9%
Operating Lease, Liability, Current 3.84M USD +5.63%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.64M USD -5.58%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.85M USD +4.25%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 692K USD -48.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.64M USD +10.4%
Deferred Tax Assets, Operating Loss Carryforwards 83.4M USD +14.7%
Unrecognized Tax Benefits 22.2M USD +101%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.19M USD -39.3%
Share-based Payment Arrangement, Expense 51.4M USD +34.4%